Mike Hollan

In the first part of our conversation with Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, he provides a broad overview of the possible positive and negative impacts of FDA’s Priority Review Voucher Program.

Craig Ackerman, partner in the Alexander Group and lead of its medical device practice, discusses how AI is being used and whether pharma companies should brace for the bubble to pop.

Olympia Pharmaceutical’s CEO discusses the company’s expansion into Mississippi.

Dr. Jaspal Singh explains some of the barriers that prevent cancer patients from getting biomarker testing early in their treatment journey.

Craig Ackerman, partner in the Alexander Group and lead of its medical device practice, explains the differences in strategy based on which region you’re strategizing for.

The agreement brings Cidara’s potential flu vaccine under Merck’s umbrella.

Craig Ackerman, partner in the Alexander Group and lead of its medical device practice, discusses how events from the past few years have shaped the current market.

eClinical Solutions' chief delivery officer highlights challenges and opportunities for innovation and health equity.

The stock increased after positive Q3 earnings and deals with the Trump administration.

The Swiss region hopes to attract pharma companies looking to escape uncertainty in the US market.

Novo Nordisk presented the findings at the AASLD 76th annual meeting.

GLP-1 medications will be available on TrumpRx for discounted rates.

The motion is part of the state’s lawsuit against the Tylenol-maker based on unproven autism claims.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

The personal care corporation will add Tylenol to its portfolio, along with the rest of Kenvue’s brands.

There are conflicting reports as to the cause, although it appears to be related to a lawsuit that alleges inappropriate conduct.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

The move could signal a potential partnership between Eli Lilly and TrumpRx.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

Texas filed its lawsuit just days before Kennedy made his remarks.

The company will no longer be spinning CSL Seqirus next June.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

The agency says the new guidelines will simplify the requirements to bring biosimilars to market.

President Trump’s claims about $150 weight-loss medication are causing investors to question the importance of the contents of the current earnings reports.

Chris O’Dell, SVP of market solutions at Turquoise Health, explains why the administration’s efforts aren’t likely to impact generics in the near future.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

Chris O’Dell, SVP of market solutions at Turquoise Health, discusses the impact on the various middle-men involved in drug-pricing.

The group says that willpower alone won’t help most people.

Chris O’Dell, SVP of market solutions at Turquoise Health, details the ways that the President’s new program differs from previous programs.

Researchers reveal that GLP-1 medication Ozempic may reduce biological age, offering new hope in the fight against aging and related health issues.